Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2022
Novavax’s COVID-19 booster has been approved for adults, Health Canada says
17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...
Posted by Michael Wonder on 17 Nov 2022
NICE recommends 3 treatments for COVID-19 in draft guidance
16 November 2022 - Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation. ...
Posted by Michael Wonder on 17 Nov 2022
New COVID-19 vaccines for eligible Australians
15 November 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on ...
Posted by Michael Wonder on 16 Nov 2022
TGA grants provisional determination to Pfizer’s COVID-19 bivalent (Comirnaty Bivalent Omicron BA.4/BA.5) booster dose vaccine
16 November 2022 - On 15 November 2022, the TGA granted a provisional determination to Pfizer’s bivalent COVID-19 vaccine candidate: tozinameran ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
15 November 2022 - On 29 September 2022, the TGA provisionally approved Comirnaty (Pfizer) COVID-19 vaccine for use in children ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI update on boosters following COVID-19 meeting on 11 November 2022
15 November 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November ...
Posted by Michael Wonder on 15 Nov 2022
COVID-19 vaccine safety report (3 November 2022)
3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 Nov 2022
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine booster for children 5 through 11 years of age in European Union
10 November 2022 - Pfizer and BioNTech today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Comirnaty Original/Omicron ...
Posted by Michael Wonder on 11 Nov 2022
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission
10 November 2022 - First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe. ...
Posted by Michael Wonder on 08 Nov 2022
New COVID-19 variant leads to increase in cases
8 November 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, on the increase in COVID-19 cases ...
Posted by Michael Wonder on 06 Nov 2022
Moderna receives Health Canada authorisation for second Omicron targeting bivalent booster
4 November 2022 - mRNA-1273.222 targets BA.4/BA.5 Omicron sub-variants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which ...
Posted by Michael Wonder on 03 Nov 2022
Health Canada authorises second bivalent COVID-19 booster targeting the Omicron BA.4/5 variants
3 November 2022 - Today, Health Canada authorised an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron ...
Posted by Michael Wonder on 01 Nov 2022
Vaxzevria receives full marketing authorisation in the EU for the prevention of COVID-19
1 November 2022 - AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted full marketing authorisation in the European Union. ...
Posted by Michael Wonder on 31 Oct 2022
Expanded access to COVID-19 oral antiviral treatments on the PBS
1 November 2022 - Expanded eligibility criteria for COVID-19 oral anti-viral treatments (Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir) ...